Literature DB >> 12435065

Fatal outcome from meningococcal disease--an association with meningococcal phenotype but not with reduced susceptibility to benzylpenicillin.

Caroline L Trotter, Andrew J Fox1, Mary E Ramsay, Francesca Sadler1, Stephen J Gray1, Richard Mallard1, Edward B Kaczmarski1.   

Abstract

Penicillin has been the mainstay of treatment for meningococcal disease. Isolates of Neisseria meningitidis that are less susceptible to penicillin have been reported in several countries and in recent years have become more common. The clinical significance of this reduced susceptibility has not been investigated on a large scale. Hence, N. meningitidis isolates from culture-confirmed cases of meningococcal disease in England and Wales, between 1993 and 2000, were routinely serogrouped, serotyped and tested for susceptibility to penicillin. These data were linked to death registrations and analysed retrospectively. The changing trends in susceptibility were described and multivariate logistic regression was used to examine associations between strain characteristics and fatal outcome. The frequency of N. meningitidis isolates less susceptible to penicillin increased from < 6% in 1993 to > 18% in 2000. In particular, isolates expressing serogroup C with serotype 2b and serogroup W135 had a higher frequency of reduced penicillin susceptibility (49% and 55%, respectively). There was no evidence of an association between fatal outcome and infection with a less penicillin-susceptible isolate. Fatal outcome was associated with serogroup and serotype, with the odds of death for cases infected with C:2a and B:2a strains three-fold higher when compared with the baseline. For this large dataset the serogroup and serotype of the infecting strain influenced mortality from meningococcal disease and may be markers for hypervirulence. No association was found between reduced penicillin susceptibility and fatal outcome, but the increasing frequency of isolates less susceptible to penicillin highlights the need for continued surveillance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12435065     DOI: 10.1099/0022-1317-51-10-855

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  11 in total

Review 1.  The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.

Authors:  Robert Welte; Caroline L Trotter; W John Edmunds; Maarten J Postma; Philippe Beutels
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

Review 2.  Revealing the molecular signatures of host-pathogen interactions.

Authors:  Chiea-Chuen Khor; Martin L Hibberd
Journal:  Genome Biol       Date:  2011-10-19       Impact factor: 13.583

3.  Epidemiology of invasive meningococcal disease with decreased susceptibility to penicillin in Ontario, Canada, 2000 to 2006.

Authors:  Elizabeth M Brown; David N Fisman; Steven J Drews; Sharon Dolman; Prasad Rawte; Shirley Brown; Frances Jamieson
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

4.  The natural history of meningococcal carriage and disease.

Authors:  C L Trotter; N J Gay; W J Edmunds
Journal:  Epidemiol Infect       Date:  2005-10-20       Impact factor: 2.451

5.  Laboratory-based surveillance of patients with bacterial meningitis in Egypt (1998-2004).

Authors:  S Afifi; M O Wasfy; M A Azab; F G Youssef; G Pimentel; T W Graham; H Mansour; N Elsayed; K Earhart; R Hajjeh; F Mahoney
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-05       Impact factor: 5.103

Review 6.  Impact of vaccination on meningococcal epidemiology.

Authors:  Paola Stefanelli; Giovanni Rezza
Journal:  Hum Vaccin Immunother       Date:  2015-10-29       Impact factor: 3.452

7.  Frequent capsule switching in 'ultra-virulent' meningococci - Are we ready for a serogroup B ST-11 complex outbreak?

Authors:  Jay Lucidarme; Aiswarya Lekshmi; Sydel R Parikh; James E Bray; Dorothea M Hill; Holly B Bratcher; Steve J Gray; Anthony D Carr; Keith A Jolley; Jamie Findlow; Helen Campbell; Shamez N Ladhani; Mary E Ramsay; Martin C J Maiden; Ray Borrow
Journal:  J Infect       Date:  2017-06-01       Impact factor: 6.072

8.  Laboratory-based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006-2010.

Authors:  Ana Belén Ibarz-Pavón; Ana Paula Lemos; Maria Cecilia Gorla; Mabel Regueira; Jean-Marc Gabastou
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

9.  A decade of invasive meningococcal disease surveillance in Poland.

Authors:  Anna Skoczyńska; Izabela Waśko; Alicja Kuch; Marcin Kadłubowski; Agnieszka Gołębiewska; Małgorzata Foryś; Marlena Markowska; Patrycja Ronkiewicz; Katarzyna Wasiak; Aleksandra Kozińska; Bożena Matynia; Waleria Hryniewicz
Journal:  PLoS One       Date:  2013-08-20       Impact factor: 3.240

10.  Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage.

Authors:  Jay Lucidarme; Dorothea M C Hill; Holly B Bratcher; Steve J Gray; Mignon du Plessis; Raymond S W Tsang; Julio A Vazquez; Muhamed-Kheir Taha; Mehmet Ceyhan; Adriana M Efron; Maria C Gorla; Jamie Findlow; Keith A Jolley; Martin C J Maiden; Ray Borrow
Journal:  J Infect       Date:  2015-07-28       Impact factor: 6.072

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.